I’ve told my students that covering health care conflicts of interest could be a fulltime beat – and you still wouldn’t keep up.
In the first half of this year, the drug giant Eli Lilly paid 3,971 doctors and other medical professionals an average of about $11,230 each. The payments were for participating in an average of 12 speaking or consulting engagements during those six months, according to a company spokeswoman.
Dr. Manoj V. Waikar, for example, a physician among the top five earners this year, received $74,850 for consulting and speaking at 51 events, according to Lilly’s on-line faculty registry. The company caps payments at $75,000 for each health care provider in any calendar year.
He’s an adjunct instructor at Stanford. Stanford’s ban on regular faculty members participating in drug company speakers’ bureaus doesn’t apply to adjuncts – as long as they’re not using the Stanford name.
As blogger Merrill Goozner writes:
Waikar gave 51 talks last year to earn that $75,000. That’s one a week, week after week, all year at $1,500 a pop. Think about it. Same slides, same talk. Just show up for two hours and the check is in the mail. Do that for three companies and you’re earning over $200,000 annually. And you were wondering how the man earns a living on an adjunct faculty’s salary.
Meantime, it doesn’t take the NY Times to dig into conflict of interest issues. A student journalist with the Minnesota Daily points out how medical students receive free textbooks from drug companies promoting their products. Case in point: an otolaryngology text given out by a company making an ear infection drug – with the company’s logo on it, and with the beginning of each chapter crediting the drug company.
The student journalist also pointed out that the University of Minnesota has no policy to ban such practices.
It’s good that this student journalist starts looking at conflict of interest issues now. If she stays on this beat, she’s going to be busy on COI stories for a long time.
Opinions on other issues in news, journals, PR, advertising, marketing
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Emma C
November 4, 2009 at 9:52 amNew internship, slowly learning that, quite sadly, COI exists beyond the health spectrum in higher ed. Hopefully will get time to help another reporter on this topic.
Any news #UMN med school COI? It took 2 of us last year to stay abreast of all that last year.
Ivan Oransky
November 4, 2009 at 12:49 pmThe U of M student journalist might be interested to know that a former student journalist named Joshua Sharfstein — the name will be familiar because he is now principal deputy commissioner of the FDA — took up the pharma-sponsored textbooks as a Harvard Med student in the early 1990s:
http://www.thecrimson.com/article.aspx?ref=116513
Ivan Oransky, MD
Executive Editor
Reuters Health
http://www.reutershealth.com
http://twitter.com/ivanoransky
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like